CClinicalTrials.gg
RecruitingNCT05922397Updated Feb 13, 2025

Placenta Accreta Spectrum Topographic Classification

An observational study in Placenta Accreta, sponsored by Fundacion Clinica Valle del Lili. Recruiting at 1 site in Colombia. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-13.

Sponsored by Fundacion Clinica Valle del Lili · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
326
Ages
18 Years to 55 Years
Sex
Female
01

Study summary

The present study is a prospective multicenter study consisting of a cohort of patients with prenatal or intraoperative diagnosis of PAS, evaluating the clinical outcomes of the group of patients found in each category of the topographic classification. In addition, an approach to evaluate the acceptability of this classification among the obstetrician-gynecologists of the participating medical centers will be included.

Read the detailed description

The aim of this study is to describe the demographic and clinical characteristics of patients with a diagnosis of placenta accreta spectrum, and to determine the correlation between the topographic classification and the clinical outcomes found in the study. Finally, to evaluated whether the proposed classification is accepted by the obstetrician-gynecologists of the participating centers that manage placenta accreta spectrum patients.

It is an observational, multicentric study of a prospective cohort, in which data will be obtained from the medical records and other documents in each participating center, which are considered to be of routine use in day-to-day clinical practice. The study of the outcomes proposed in this protocol will be limited to those recorded in the clinical records and will be taken into account until the participant is discharged from the hospital, during which a surgical intervention was performed due to the suspicion or diagnosis of PAS.

It is projected that the period of patient enrollment will last 2 years, counting on from the first participant included. The study population is pregnant patients with a diagnosis of placenta accreta spectrum who visits any of the participating medical centers, and also obstetrician-gynecologists working in participating medical centers.

The centers invited to participate are hospitals or clinics that already have knowledge in how to apply the surgical staging of PAS, and the topographic classification and have experience using it.

02

Conditions studied

  • Placenta Accreta

Browse trials for

Keywords

  • Pregnancy outcomes
  • Topographic classification
  • Placenta accreta
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

  • Pregnant patients with a diagnosis of placenta accreta spectrum who visits any of the participating medical centers.
  • Obstetrician-gynecologists working in participating medical centers.

Inclusion criteria

  • Pregnant woman over 18 years old.
  • Prenatal diagnosis by ultrasound or MRI of Placenta Accreta Spectrum (PAS), regardless of the suspected degree of severity of the disease.
  • Case requiring surgical management, either as scheduled or emergent procedure.
  • Application of the topographic classification of placenta accreta spectrum during laparotomy.

Exclusion criteria

Exclusion Criteria:

  • None.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
326 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Days of postoperative hospitalization

    Number of days the patient was hospitalized from the day of surgery to the day of discharge

    Time frame: From the day the surgery is performed until the day of discharge or the date of death from any cause, whichever occurs first, evaluated up to 42 days.

  2. Volume of intraoperative blood loss

    Surgical bleeding calculated in milliliters

    Time frame: During surgery

  3. Bladder injury

    Number of patients who had Bladder injuries

    Time frame: Up to 42 days postpartum

  4. Surgical reintervention

    Number of patients who need surgical reoperation after index surgery

    Time frame: Up to 42 days postpartum

  5. Complications associated with vascular interventions

    The patient presented thrombosis or other complication during post-surgery associated with vascular interventions.

    Time frame: Up to 42 days postpartum

  6. Maternal death

    Does the patient die during this study

    Time frame: 24 months

06

Study locations

1 of 1 sites recruiting
  • Fundación Valle del Lili
    Cali, Colombia
    • Albaro J Nieto-Calvache, M.D. · Contact · albaro.nieto@fvl.org.co · 6023319090
    • Albaro J Nieto-Calvache, M.D. · Principal investigator
    Recruiting
07

References and documents

Publications

  • Palacios-Jaraquemada JM, Fiorillo A, Hamer J, Martinez M, Bruno C. Placenta accreta spectrum: a hysterectomy can be prevented in almost 80% of cases using a resective-reconstructive technique. J Matern Fetal Neonatal Med. 2022 Jan;35(2):275-282. doi: 10.1080/14767058.2020.1716715. Epub 2020 Jan 26. PubMed 31984808 ↗
  • Kingdom JC, Hobson SR, Murji A, Allen L, Windrim RC, Lockhart E, Collins SL, Soleymani Majd H, Alazzam M, Naaisa F, Shamshirsaz AA, Belfort MA, Fox KA. Minimizing surgical blood loss at cesarean hysterectomy for placenta previa with evidence of placenta increta or placenta percreta: the state of play in 2020. Am J Obstet Gynecol. 2020 Sep;223(3):322-329. doi: 10.1016/j.ajog.2020.01.044. Epub 2020 Jan 30. PubMed 32007492 ↗
  • Palacios-Jaraquemada JM, D'Antonio F. Possible limitation to use the International Federation of Gynecology and Obstetrics classification of placenta accreta spectrum. Am J Obstet Gynecol. 2020 Dec;223(6):944. doi: 10.1016/j.ajog.2020.06.033. Epub 2020 Jun 19. No abstract available. PubMed 32565238 ↗
  • Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aryananda RA, Rodriguez F, Ordonez CA, Messa Bryon A, Calvache JPB, Lopez J, Campos CI, Mejia M, Rengifo M, Galliadi LMV, Maya J, Zambrano MA, Aguayo IP, Carabali IG, Burgos JM. How to identify patients who require aortic vascular control in placenta accreta spectrum disorders? Am J Obstet Gynecol MFM. 2022 Jan;4(1):100498. doi: 10.1016/j.ajogmf.2021.100498. Epub 2021 Oct 2. PubMed 34610485 ↗
  • Jauniaux E, Jurkovic D, Hussein AM, Burton GJ. New insights into the etiopathology of placenta accreta spectrum. Am J Obstet Gynecol. 2022 Sep;227(3):384-391. doi: 10.1016/j.ajog.2022.02.038. Epub 2022 Mar 3. PubMed 35248577 ↗
  • Garmi G, Salim R. Epidemiology, etiology, diagnosis, and management of placenta accreta. Obstet Gynecol Int. 2012;2012:873929. doi: 10.1155/2012/873929. Epub 2012 May 7. PubMed 22645616 ↗
  • Jauniaux E, Ayres-de-Campos D, Langhoff-Roos J, Fox KA, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO classification for the clinical diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2019 Jul;146(1):20-24. doi: 10.1002/ijgo.12761. PubMed 31173360 ↗
  • Collins SL, Stevenson GN, Al-Khan A, Illsley NP, Impey L, Pappas L, Zamudio S. Three-Dimensional Power Doppler Ultrasonography for Diagnosing Abnormally Invasive Placenta and Quantifying the Risk. Obstet Gynecol. 2015 Sep;126(3):645-653. doi: 10.1097/AOG.0000000000000962. PubMed 26214694 ↗
  • Hussein AM, Elbarmelgy RA, Elbarmelgy RM, Thabet MM, Jauniaux E. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder. Ultrasound Obstet Gynecol. 2022 Apr;59(4):474-482. doi: 10.1002/uog.23732. Epub 2022 Mar 8. PubMed 34225385 ↗
  • Allen L, Jauniaux E, Hobson S, Papillon-Smith J, Belfort MA; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management. Int J Gynaecol Obstet. 2018 Mar;140(3):281-290. doi: 10.1002/ijgo.12409. No abstract available. PubMed 29405317 ↗
  • Sentilhes L, Kayem G, Chandraharan E, Palacios-Jaraquemada J, Jauniaux E; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Conservative management. Int J Gynaecol Obstet. 2018 Mar;140(3):291-298. doi: 10.1002/ijgo.12410. No abstract available. PubMed 29405320 ↗
  • Melber DJ, Berman ZT, Jacobs MB, Picel AC, Conturie CL, Zhang-Rutledge K, Binder PS, Eskander RN, Roberts AC, McHale MT, Ramos GA, Ballas J, Kelly TF. Placenta Accreta Spectrum Treatment With Intraoperative Multivessel Embolization: the PASTIME protocol. Am J Obstet Gynecol. 2021 Oct;225(4):442.e1-442.e10. doi: 10.1016/j.ajog.2021.07.001. Epub 2021 Jul 7. PubMed 34245679 ↗
  • Shamshirsaz AA, Fox KA, Erfani H, Clark SL, Salmanian B, Baker BW, Coburn M, Shamshirsaz AA, Bateni ZH, Espinoza J, Nassr AA, Popek EJ, Hui SK, Teruya J, Tung CS, Jones JA, Rac M, Dildy GA, Belfort MA. Multidisciplinary team learning in the management of the morbidly adherent placenta: outcome improvements over time. Am J Obstet Gynecol. 2017 Jun;216(6):612.e1-612.e5. doi: 10.1016/j.ajog.2017.02.016. Epub 2017 Feb 16. PubMed 28213059 ↗
  • Hussein AM, Kamel A, Raslan A, Dakhly DMR, Abdelhafeez A, Nabil M, Momtaz M. Modified cesarean hysterectomy technique for management of cases of placenta increta and percreta at a tertiary referral hospital in Egypt. Arch Gynecol Obstet. 2019 Mar;299(3):695-702. doi: 10.1007/s00404-018-5027-7. Epub 2019 Jan 4. PubMed 30607590 ↗
  • Sentilhes L, Seco A, Azria E, Beucher G, Bonnet MP, Branger B, Carbillon L, Chiesa C, Crenn-Hebert C, Dreyfus M, Dupont C, Fresson J, Huissoud C, Langer B, Morel O, Patrier S, Perrotin F, Raynal P, Rozenberg P, Rudigoz RC, Vendittelli F, Winer N, Deneux-Tharaux C, Kayem G; PACCRETA Study Group. Conservative management or cesarean hysterectomy for placenta accreta spectrum: the PACCRETA prospective study. Am J Obstet Gynecol. 2022 Jun;226(6):839.e1-839.e24. doi: 10.1016/j.ajog.2021.12.013. Epub 2021 Dec 14. PubMed 34914894 ↗
  • Whittington JR, Pagan ME, Nevil BD, Kalkwarf KJ, Sharawi NE, Hughes DS, Sandlin AT. Risk of vascular complications in prophylactic compared to emergent resuscitative endovascular balloon occlusion of the aorta (REBOA) in the management of placenta accreta spectrum. J Matern Fetal Neonatal Med. 2022 Aug;35(16):3049-3052. doi: 10.1080/14767058.2020.1802717. Epub 2020 Aug 11. PubMed 32781879 ↗
  • Nieto-Calvache AJ, Hidalgo-Cardona A, Lopez-Giron MC, Rodriguez F, Ordonez C, Garcia AF, Mejia M, Pabon-Parra MG, Burgos-Luna JM. Arterial thrombosis after REBOA use in placenta accreta spectrum: a case series. J Matern Fetal Neonatal Med. 2022 Nov;35(21):4031-4034. doi: 10.1080/14767058.2020.1846178. Epub 2020 Nov 18. PubMed 33207992 ↗
  • Chandraharan E. Need for an urgent paradigms shift in thinking to avoid serious maternal morbidity and mortality associated with PAS. Best Pract Res Clin Obstet Gynaecol. 2021 Apr;72:1-3. doi: 10.1016/j.bpobgyn.2021.04.001. No abstract available. PubMed 33894905 ↗
  • Aryananda RA, Aditiawarman A, Gumilar KE, Wardhana MP, Akbar MIA, Cininta N, Ernawati E, Wicaksono B, Joewono HT, Dachlan EG, Bachtiar CA, Kurniawati D, Virdayanti DP, Ariani G, Dekker GA, Sulistyono A. Uterine conservative-resective surgery for selected placenta accreta spectrum cases: Surgical-vascular control methods. Acta Obstet Gynecol Scand. 2022 Jun;101(6):639-648. doi: 10.1111/aogs.14348. Epub 2022 Mar 17. PubMed 35301710 ↗
  • Palacios Jaraquemada JM, Garcia Monaco R, Barbosa NE, Ferle L, Iriarte H, Conesa HA. Lower uterine blood supply: extrauterine anastomotic system and its application in surgical devascularization techniques. Acta Obstet Gynecol Scand. 2007;86(2):228-34. doi: 10.1080/00016340601089875. PubMed 17364288 ↗
  • Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aryananda R, Basanta N, Aguilera R, Benavides JP, Lopez J, Campos C, Valencia L, Arboleda K, Cabrera V, Cabrera J, Tavera-Martinez GM, Sinisterra S, Maya J, Pena T, Burgos-Luna JM, Messa A. How to perform the one-step conservative surgery for placenta accreta spectrum move by move. Am J Obstet Gynecol MFM. 2023 Feb;5(2):100802. doi: 10.1016/j.ajogmf.2022.100802. Epub 2022 Nov 11. PubMed 36372188 ↗
  • Sargent W, Collins SL. Are women antenatally diagnosed with abnormally invasive placenta receiving optimal management in England? An observational study of planned place of delivery. Acta Obstet Gynecol Scand. 2019 Mar;98(3):337-341. doi: 10.1111/aogs.13487. Epub 2018 Nov 15. PubMed 30368768 ↗
  • Brown AD, Hart JM, Modest AM, Hess PE, Abbas AM, Nieto-Calvache AJ, Bhide A, Lim B, Dunjin C, Palacios-Jaraquemada J, Sentilhes L, Soma-Pillay P, Aryananda RA, Hantoushzadeh S, Wang S, Shamshirsaz AA, Shainker SA. Geographic variation in management of patients with placenta accreta spectrum: An international survey of experts (GPASS). Int J Gynaecol Obstet. 2022 Jul;158(1):129-136. doi: 10.1002/ijgo.13960. Epub 2021 Oct 28. PubMed 34610154 ↗
  • Nieto-Calvache AJ, Lopez-Giron MC, Nieto-Calvache A, Messa-Bryon A, Benavides-Calvache JP, Burgos-Luna JM. A nationwide survey of centers with multidisciplinary teams for placenta accreta patient care in Colombia, observational study. J Matern Fetal Neonatal Med. 2022 Jun;35(12):2331-2337. doi: 10.1080/14767058.2020.1786052. Epub 2020 Jul 6. PubMed 32627610 ↗
  • Nieto-Calvache AJ, Palacios-Jaraquemada JM, Hidalgo A, Vergara-Galliadi LM, Cortes Charry R, Aguilera Daga LR, Verastegui Goyzueta R, Osanan G, Fernandez J, Corrales F, Mereci W, Yuen-Chon V, Guevara E, Zuniga LA, Giron, Turcios FE, Munoz H, Perez AM, Meade P, Basanta N, Pineda JP. Management practices for placenta accreta spectrum patients: a Latin American hospital survey. J Matern Fetal Neonatal Med. 2022 Dec;35(25):6104-6111. doi: 10.1080/14767058.2021.1906858. Epub 2021 Apr 11. PubMed 33843408 ↗
  • Nieto AJ, Echavarria MP, Carvajal JA, Messa A, Burgos JM, Ordonez C, Benavidez JP, Mejia M, Lopez L, Fernandez PA, Escobar MF. Placenta accreta: importance of a multidisciplinary approach in the Colombian hospital setting. J Matern Fetal Neonatal Med. 2020 Apr;33(8):1321-1329. doi: 10.1080/14767058.2018.1517328. Epub 2018 Sep 25. PubMed 30153754 ↗
  • Einerson BD, Watt MH, Sartori B, Silver R, Rothwell E. Lived experiences of patients with placenta accreta spectrum in Utah: a qualitative study of semi-structured interviews. BMJ Open. 2021 Nov 3;11(11):e052766. doi: 10.1136/bmjopen-2021-052766. PubMed 34732490 ↗
  • Nieto-Calvache AJ, Palacios-Jaraquemada JM, Aguilera LR, Arriaga W, Colonia A, Aryananda RA, Nieto-Calvache AS, Maya J, Vergara-Galliadi LM, Messa Bryon A. Telemedicine facilitates surgical training in placenta accreta spectrum. Int J Gynaecol Obstet. 2022 Jul;158(1):137-144. doi: 10.1002/ijgo.14000. Epub 2021 Nov 20. PubMed 34714947 ↗

Study documents

  • Protocol and statistical analysis plan · Feb 22, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No — We do not plan to share individual participant data, since we are not allowed to share information concerning the medical history of our patients or health workers

08

Registry details

Key details

Study ID
NCT05922397
Lead sponsor
Fundacion Clinica Valle del Lili
Responsible party
Sponsor
First posted
Jun 28, 2023
Start date
May 21, 2023
Primary completion
Jun 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Feb 13, 2025

Study contacts

Albaro J Nieto-Calvache, MD
Contact
albaro.nieto@fvl.org.co
6023319090 ext. 4022
Daniela Sarria-Ortiz, MD
Contact
daniela.sarria.or@fvl.org.co
6023319090 ext. 3836
Albaro J Nieto-Calvache, MD
principal investigator · Fundacion Clinica Valle del Lili

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion